IDBS and Titian to Provide Complete Solution for Drug Discovery Market
News Oct 03, 2007
IDBS has announced a strategic partnership with Titian Software Ltd (London, UK).
Titian specializes in sample management and provides inventory management solutions to enable the supply of compounds, reagents and biological samples to vital scientific research processes. Titian has worked with a broad range of customers, including major global pharmaceutical and smaller screening organizations.
IDBS and Titian have entered into a strategic collaboration whereby they will provide a comprehensive, customer-focused solution for life science organizations. IDBS’ applications will interact with Titian’s Mosaic inventory management system to streamline customer workflow, increasing screening efficiency, throughput and data integrity.
“This agreement represents a great opportunity to tailor our products towards our customers’ needs. IDBS’ industry-leading data management capabilities will complement our expertise in inventory management, strengthening our value proposition to the life science industry,” commented Richard Fry, co-founder and Commercial Director of Titian.
Neil Kipling, founder and CEO of IDBS, commented: “Increasingly our customers have indicated a need for flexible inventory management. Our customers will benefit from the direct integration with ActivityBase, providing them with the best possible solution for managing their screening and discovery data.”
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE